Edit
MacuLogix - The AMD Experts
https://www.maculogix.com/?portfolioCats=34,23,29,35,22,24,30,25,28,31#new_tabLast activity: 12.05.2022
Active
MacuLogix® is a company that equips eye care professionals with the technology, tools, and education needed to help identify and manage age-related macular degeneration (AMD) patients early, before irreversible vision loss has occurred. We can help you deliver better patient care with the scientifically validated AdaptDx Pro®.
The AdaptDx Pro is a simple, fully automated dark adaptometer. It measures dark adaptation speed, which can be used to identify AMD with 90% sensitivity.
The AdaptDx Pro is a simple, fully automated dark adaptometer. It measures dark adaptation speed, which can be used to identify AMD with 90% sensitivity.
Location: United States, Pennsylvania, Harrisburg
Employees: 51-200
Phone: +1 717-914-4067
Total raised: $57.3M
Founded date: 2013
Investors 3
Funding Rounds 4
| Date | Series | Amount | Investors |
| 04.03.2019 | Series D | $38.7M | Vivo Capit... |
| 14.08.2018 | - | $10M | - |
| 31.07.2015 | - | $5M | - |
| 11.03.2013 | Series A | $3.6M | - |
Mentions in press and media 15
| Date | Title | Description |
| 12.05.2022 | MacuLogix Reaches New Milestone with One Million Dark Adaptation Tests | AdaptDx Pro can be used in any eye care office to help test dark adaptation speed, which is useful in the detection of age-related macular degeneration As more and more practices embrace dark adaptation testing, AdaptDx technology has becom... |
| 07.03.2019 | Pennsylvania-Based Eye Care Company MacuLogix Raises $38.7 Million | MacuLogix, a Harrisburg, Pennsylvania-based company that equips eye care professionals with the instruments, tools, and education they need to effectively diagnose and treat patients with age-related macular degeneration (AMD), has raised $... |
| 04.03.2019 | MacuLogix Raises $38.7M in Series D | HARRISBURG, PA, MacuLogix announced it completed a Series D round of financing totaling $38.7 million. >> Click here for more funding data on MacuLogix >> To export MacuLogix funding data to PDF and Excel, click here Macu... |
| 04.03.2019 | MacuLogix Raises $38.7M in Series D Financing | MacuLogix, Inc., a Harrisburg, PA-based company equipping eye care professionals with tools to diagnose and treat patients with age-related macular degeneration (AMD), completed a $38.7m Series D financing. The round was led by new investor... |
| 04.03.2019 | MacuLogix Raises $38.7M in Series D Financing Led by Vivo Capital | MacuLogix, Inc., the only company to equip eye care professionals with the instrument, tools and education needed to effectively diagnose and treat patients with age-related macular degeneration (AMD), today announced it completed a Series ... |
| 04.03.2019 | Daily funding roundup - March 4th, 2019 | Emmersion Learning raised $2.4M; QuotaPath raised $3.5M; Scytale raised $5: RightRice raised $5M Emmersion Learning: Emmersion Learning is dedicated to elevating the productivity and success of individuals and businesses by enhancing their ... |
| 14.08.2018 | Medical Device Company MacuLogix Receives $10M Loan Facility | MacuLogix, a Middletown, PA-based medical device company in the optometry and ophthalmology industry, received a $10m loan facility. Horizon Technology Finance Corporation (NASDAQ: HRZN), a specialty finance company that provides capital in... |
| 18.07.2018 | Horizon Technology Finance Leads $10 Million Loan Facility for MacuLogix | Horizon Technology Finance Corporation (NASDAQ: HRZN), a leading specialty finance company that provides capital in the form of secured loans to venture capital backed companies in the technology, life science, healthcare information and se... |
| 18.10.2017 | Gemini Therapeutics closes $42.5M Series A for dry age-related macular degeneration therapy | Atlas Venture, Lightstone Ventures and OrbiMed co-led the Series A, according to a news release. They also took part in the seed round last year. James McLaughlin, Gemini Therapeutics cofounder and CEO, said that the company focuses on pati... |
| 18.07.2017 | LSGPA Invests an Additional $500,000 in MacuLogix | HARRISBURG, Pa.--(BUSINESS WIRE)--The Life Sciences Greenhouse of Central Pennsylvania (LSGPA) announced today an additional investment of $500,000 in MacuLogix, Inc. The investment was part of a syndicate with other, unnamed investors and ... |
Show more